


RNAi THERAPEUTICS AND THE ELEVATE REGISTRY:

Shaping the Future of AHP Patient Care

In the last 20 years, RNAi therapeutics have evolved from bench to bedside and are now a treatment option for patients with rare and prevalent diseases.¹

Hear from Ivan Zlatev PhD, Director of Research, and Mary-Jean Fanelli MD, Executive Director, Global Medical Affairs, of Alnylam Pharmaceuticals, as they share their insights into the development of RNAi therapeutics and ELEVATE, a registry of patients with AHP.²



Ivan Zlatev PhD

Director of Research,
Alnylam Pharmaceuticals



Mary-Jean Fanelli MD

Executive Director, Global Medical
Affairs, Alnylam Pharmaceuticals

Join us for an Alnylam Pharmaceuticals-sponsored symposium

RNAi THERAPEUTICS AND THE ELEVATE REGISTRY: Shaping the Future of AHP Patient Care

5th September 2022, 07:30–08:30 (EET)
Grand Hotel Millennium, Sofia, Bulgaria

AHP, acute hepatic porphyria; EET, Eastern European Time; ICPP, International Conference on Porphyrins and Porphyrins; RNAi, ribonucleic acid interference.

This symposium will contain information on products developed and marketed by Alnylam Pharmaceuticals.

This symposium is organised and funded by Alnylam Pharmaceuticals, for healthcare professionals only.

This symposium is not a Continuing Education (CE) activity.

References:

1. Fire A et al. *Nature* 1998;391:806–811; 2. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT04883905> (Accessed August 2022).